Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06873789 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
A Phase 1 study of Advanced Solid Tumors and Solid Tumors, sponsored by Incyte Corporation.
- Active
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 9
- Study locations
NCT06873789: Active Phase 1 study of Advanced Solid Tumors and Solid Tumors, sponsored by Incyte Corporation.
NCT06873789 is a Phase 1 study of Advanced Solid Tumors and Solid Tumors that is active but no longer recruiting, run by Incyte Corporation. The registered enrollment target is 9 participants, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (95% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06873789, a Phase 1 study of Advanced Solid Tumors and Solid Tumors, is active but no longer recruiting, sponsored by Incyte Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 9
- Study locations
Study Summary
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors.
Primary Outcome
Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol.
Conditions Studied
Interventions
- DRUG Retifanlimab
- DRUG INCB177054
Study Locations (9)
California
- The Angeles Clinic and Research Institute - Los Angeles
- Valkyrie Clinical Trials - Panorama City
Florida
- University of Florida Health Shands Hospital - Gainesville
Michigan
- Cancer and Hematology Centers of Western Michigan-Start Midwest - Grand Rapids
New Jersey
- Hackensack University Medical Center - Hackensack
North Carolina
- Carolina Bio Oncology - Huntersville
Oregon
- Providence Cancer Institute Franz Clinic - Portland
Pennsylvania
- Upmc Cancercenter - Pittsburgh
Texas
- South Texas Accelerated Research Therapeutics - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2025-06-30 |
| Est. Completion | 2028-10-30 |
| Phase | Phase 1 |
What the registry record for NCT06873789 still lists
NCT06873789 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Retifanlimab is the first listed.
NCT06873789 lists 9 locations in 8 states (California, Florida, Michigan).
Frequently Asked Questions
What is clinical trial NCT06873789 about?
NCT06873789 is a clinical study titled "A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors". This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors.
What is the current status of trial NCT06873789?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2025-06-30. Estimated completion is 2028-10-30.
What conditions does trial NCT06873789 study?
This clinical trial studies the following conditions: Advanced Solid Tumors, Solid Tumors, Metastatic Solid Tumors.
What interventions are being tested in trial NCT06873789?
The interventions under investigation include: Retifanlimab (DRUG), INCB177054 (DRUG).
Who is sponsoring clinical trial NCT06873789?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06873789 being conducted?
This trial has 9 study locations across California, Florida, Michigan, New Jersey, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06873789's enrollment target sits among peer trials
9 140th of 144 higher than 4 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI